Holly A. Swartz, MD

University of Pittsburgh, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania

  • 10Articles
  • 38.5KReads
  • 2002–2026Active
  • 40Collaborators
  • 149Citations

About

Holly A. Swartz, MD, is affiliated with the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. Her publications with Psychiatrist.com span from 2002 to 2025, focusing on topics including bipolar disorder, psychotherapy, depression, psychiatry, suicide, and weight. She has frequently collaborated with Andrea Fagiolini, Ellen Frank, Michael E. Thase, Joseph F. Goldberg, and Alan G. Mallinger.

Publications

JCP
When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?
ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...
, , , et al
JCP
Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression
Original Research

Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression

September 29, 2025

There was no significant difference in suicidal ideation in those receiving IPSRT plus placebo vs IPSRT plus quetiapine. IPSRT has the potential to mitigate suicidal ideation in patients with...
, , , et al
JCP
What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?
ASCP Corner

What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?

June 2, 2025

The authors encourage the field to destigmatize the term “deprescribing” from its misappropriated usage, explicate its accurate definition, and reclaim its purposeful meaning.
, , , et al
JCP
Addressing Unmet Needs in Bipolar Disorder
Academic Highlights

Addressing Unmet Needs in Bipolar Disorder

November 16, 2022

Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are...
, ,
JCP
Original Research

Psychotherapy for Bipolar II Depression

July 11, 2017

Quetiapine has the greatest evidence of efficacy for bipolar II depression, but it is also associated with metabolic side effects. This study compared psychotherapy plus placebo or plus pharmacotherapy....
, , , et al
JCP
ASCP Corner

Cardiovascular Disease and Bipolar Disorder: Risk and Clinical Implications

December 15, 2012

,
JCP
Original Research

Pharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence

August 10, 2010

,
JCP
Article

The Use of Antidepressants in Bipolar Disorder

August 31, 2008

, , , et al
JCP
Educational Activity

The Role of Psychosocial Interventions in Bipolar II Disorder: What Do We Know?

May 11, 2008

JCP
Original Research

Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder

June 18, 2002

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe